The latest price target for InflaRx (NASDAQ:IFRX) was reported by Leerink Partners on December 3, 2025. The analyst firm set a price target for $2.00 expecting IFRX to rise to within 12 months (a possible 92.31% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for InflaRx (NASDAQ:IFRX) was provided by Leerink Partners, and InflaRx downgraded their market perform rating.

The last upgrade for InflaRx NV happened on April 6, 2023 when Guggenheim raised their price target to N/A. Guggenheim previously had a neutral for InflaRx NV.

The last downgrade for InflaRx NV happened on December 3, 2025 when Leerink Partners changed their price target from $5 to $2 for InflaRx NV.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of InflaRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for InflaRx was filed on December 3, 2025 so you should expect the next rating to be made available sometime around December 3, 2026.

While ratings are subjective and will change, the latest InflaRx (IFRX) rating was a downgraded with a price target of $5.00 to $2.00. The current price InflaRx (IFRX) is trading at is $1.04, which is out of the analyst’s predicted range.